Provasopressin expression by breast cancer cells: Implications for growth and novel treatment strategies

Breast Cancer Research and Treatment

Volumn 95, Issue 3, 2006, Pages 265-277

  Keegan, Brendan P ^a   Akerman, Bonnie L ^a   Péqueux, Christel ^b   North, William G ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Arginine vasopressin (AVP); Extracellular signal regulated kinase (ERK); Monoclonal antibody (mAb); Neurophysin related surface antigen (NRSA); Pro arginine vasopressin (proAVP); Vasopressin associated glycopeptide (VAG)

Indexed keywords

1 [5 CHLORO 3 (2 CHLOROPHENYL) 1 (3,4 DIMETHOXYBENZENESULFONYL) 2,3 DIHYDRO 3 HYDROXY 1H INDOLE 2 CARBONYL] 2 PYRROLIDINECARBOXAMIDE; 8 BROMO CYCLIC AMP; ARGIPRESSIN; BRAIN EXTRACT; CANCER EXTRACT; DEXAMETHASONE; GLYCOPEPTIDE; ISOBUTYLMETHYLXANTHINE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCLONAL ANTIBODY; PROTEIN PRECURSOR; PROVASOPRESSIN; UNCLASSIFIED DRUG; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1 RECEPTOR;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER THERAPY; CANCER TISSUE; CELL LEVEL; CELL LYSATE; CELL PROLIFERATION; CELL SURFACE; CONTROLLED STUDY; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTHALAMUS; PRIORITY JOURNAL; PROTEIN ANALYSIS;

1-METHYL-3-ISOBUTYLXANTHINE; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ARGININE VASOPRESSIN; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL PROLIFERATION; CYCLIC GMP; DEXAMETHASONE; FEMALE; GLYCOPEPTIDES; HUMANS; HYPOTHALAMUS; IMMUNOENZYME TECHNIQUES; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; OVARIAN NEOPLASMS; PHOSPHODIESTERASE INHIBITORS; PHOSPHORYLATION; PROTEIN PRECURSORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 33645227346     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-005-9024-8     Document Type: Article

References (65)

1. North WG, Valtin H, Cheng S, Hardy GR: The neurophysins: production and turnover. Prog Brain Res 60: 217-225, 1983
2. Birnbaumer M: Vasopressin receptors. Trends Endocrinol Metab 11: 406-410, 2000
3. North WG, Fay MJ, Du J: All three vasopressin receptor subtypes are expressed by small-cell carcinoma. Adv Exp Med Biol 449: 335-338, 1998
4. Van Dort C, Zhao P, Parmelee K, Capps B, Poel A, Listenberger L, Kossoris J, Wasilevich B, Murrey D, Clare P, Burnatowska-Hledin M: VACM-1, a cul-5 gene, inhibits cellular growth by a mechanism that involves MAPK and p53 signaling pathways. Am J Physiol Cell Physiol 285: C1386-1396, 2003
5. de Bree FM, Knight D, Howell L, Murphy D: Sorting of the vasopressin prohormone into the regulated secretory pathway. FEBS Lett 475: 175-180, 2000
6. de Bree FM: Trafficking of the vasopressin and oxytocin prohormone through the regulated secretory pathway. J Neuroendocrinol 12: 589-594, 2000
7. de Bree FM, Van Der Kleij AA, Nijenhuis M, Zalm R, Murphy D, Burbach JP: The hormone domain of the vasopressin prohormone is required for the correct prohormone trafficking through the secretory pathway. J Neuroendocrinol 15: 1156-1163, 2003
8. Barat C, Simpson L, Breslow E: Properties of human vasopressin precursor constructs: inefficient monomer folding in the absence of copeptin as a potential contributor to diabetes insipidus. Biochemistry 43: 8191-8203, 2004
9. Iwasaki Y, Oiso Y, Saito H, Majzoub JA: Effects of various mutations in the neurophysin/glycopeptide portion of the vasopressin gene on vasopressin expression in vitro. Tohoku J Exp Med 191: 187-202, 2000
10. Friedmann AS, Memoli VA, North WG: Vasopressin and oxytocin production by non-neuroendocrine lung carcinomas: an apparent low incidence of gene expression. Cancer Lett 75: 79-85, 1993
11. Taylor AH, Ang VT, Jenkins JS, Silverlight JJ, Coombes RC, Luqmani YA: Interaction of vasopressin and oxytocin with human breast carcinoma cells. Cancer Res 50: 7882-7886, 1990
12. Nilsson H, Eriksson LC: Growth factor induced mitogenic effects and inositol phosphate responses in primary hepatocyte cultures from normal rat liver and rat liver nodules. Carcinogenesis 15: 1821-1826, 1994
13. Schwindt TT, Forti FL, Juliano MA, Juliano L, Armelin HA: Arginine vasopressin inhibition of cyclin D1 gene expression blocks the cell cycle and cell proliferation in the mouse Y1 adrenocortical tumor cell line. Biochemistry 42: 2116-2121, 2003
14. Seckl MJ, Higgins T, Widmer F, Rozengurt E: [D-Arg1,D-Trp5,7,9,Leul1] substance P: a novel potent inhibitor of signal transduction and growth in vitro and in vivo in small cell lung cancer cells. Cancer Res 57: 51-54, 1997
15. Yamaguchi T, Pelling JC, Ramaswamy NT, Eppler JW, Wallace DP, Nagao S, Rome LA, Sullivan LP, Grantham JJ: cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int 57: 1460-1471, 2000
16. North WG, Fay MJ, Du J: MCF-7 breast cancer cells express normal forms of all vasopressin receptors plus an abnormal V2R. Peptides 20: 837-842, 1999
17. North WG, Fay MJ, Longo KA, Du J: Expression of all known vasopressin receptor subtypes by small cell tumors implies a multifaceted role for this neuropeptide. Cancer Res 58: 1866-1871, 1998
18. Giron S, Tejera AM, Ripoll GV, Gomez DE, Alonso DF: Desmopressin inhibits lung and lymph node metastasis in a mouse mammary carcinoma model of surgical manipulation. J Surg Oncol 81: 38-44, 2002
19. Pequeux C, Keegan BP, Hagelstein MT, Geenen V, Legros JJ, North WG: Oxytocin- and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway. Endocr Relat Cancer 11: 871-885, 2004
20. Verbeeck MA, Sutanto W, Burbach JP: Regulation of vasopressin messenger RNA levels in the small cell lung carcinoma cell line GLC-8: interactions between glucocorticoids and second messengers. Mol Endocrinol 5: 795-801, 1991
21. Friedmann AS, Fay MJ, Memoli VA, North WG: Factors regulating the production of vasopressin-associated human neurophysin by small-cell carcinoma of the lung: evaluation by computer-enhanced quantitative immunocytochemistry. Neuropeptides 28: 183-189, 1995
22. Coulson JM: Positive and negative regulators of the vasopressin gene promoter in small cell lung cancer. Prog Brain Res 139: 329-343, 2002
23. Coulson JM, Edgson JL, Marshall-Jones ZV, Mulgrew R, Quinn JP, Woll PJ: Upstream stimulatory factor activates the vasopressin promoter via multiple motifs, including a non-canonical E-box. Biochem J 369: 549-561, 2003
24. Coulson JM, Fiskerstrand CE, Woll PJ, Quinn JP: E-box motifs within the human vasopressin gene promoter contribute to a major enhancer in small-cell lung cancer. Biochem J 344 Pt 3: 961-970, 1999
25. Coulson JM, Fiskerstrand CE, Woll PJ, Quinn JP: Arginine vasopressin promoter regulation is mediated by a neuron-restrictive silencer element in small cell lung cancer. Cancer Res 59: 5123-5127, 1999
26. Coulson JM, Stanley J, Woll PJ: Tumour-specific arginine vasopressin promoter activation in small-cell lung cancer. Br J Cancer 80: 1935-1944, 1999
27. Coulson JM, Edgson JL, Woll PJ, Quinn JP: A splice variant of the neuron-restrictive silencer factor repressor is expressed in small cell lung cancer: a potential role in derepression of neuroendocrine genes and a useful clinical marker. Cancer Res 60: 1840-1844, 2000
28. Keegan BP, Memoli VA, North WG: Targeting the neurophysin-related cell surface antigen on small cell lung cancer cells using a monoclonal antibody against the glycopeptide region (MAG-1) of provasopressin. Mol Cancer Ther 1: 1153-1159, 2002
29. North WG, Yu XM: Vasopressin mRNA and neurophysin-related cell-surface antigen (NRSA) in small-cell carcinoma. Peptides 14: 303-307, 1993
30. North WG, Wells W, Fay MJ, Mathew RS, Donnelly EM, Memoli VA: Immunohistochemical evaluation of vasopressin expression in breast fibrocystic disease and ductal carcinoma in situ (DCIS). Endocr Pathol 14: 257-262, 2003
31. North WG, Pai S, Friedmann A, Yu X, Fay M, Memoli V: Vasopressin gene related products are markers of human breast cancer [published erratum appears in Breast Cancer Res Treat 1995;36(1):99]. Breast Cancer Res Treat 34: 229-235, 1995
32. Terasaki T, Matsuno Y, Shimosato Y, Yamaguchi K, Ichinose H, Nagatsu T, Kato K: Establishment of a human small cell lung cancer cell line producing a large amount of anti-diuretic hormone. Jpn J Cancer Res 85: 718-722, 1994
33. North WG, LaRochelle FT, Jr., Haldar J, Sawyer WH, Valtin H: Characterization of an antiserum used in a radioimmunoassay for arginine-vasopressin: implications for reference standards. Endocrinology 103: 1976-1984, 1978
34. Maggiolini M, Vivacqua A, Fasanella G, Recchia AG, Sisci D, Pezzi V, Montanaro D, Musti AM, Picard D, Ando S: The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells. J Biol Chem 279: 27008-27016, 2004
35. Beguin P, Nicolas P, Boussetta H, Fahy C, Cohen P: Characterization of the 80,000 molecular weight form of neurophysin isolated from bovine neurohypophysis. J Biol Chem 256: 9289-9294, 1981
36. North WG, Maurer H, O'Donnell JF: The neurophysins and small cell lung cancer. In: Greco F. Martinus (ed.), Biology and Management of Lung Cancer. Nijhoff, Boston, 1983, pp. 143-169
37. North WG, Yu X: Forms of neurohypophysial peptides generated by tumors, and factors regulating their expression. Regul Pept 45: 209-216, 1993
38. Alonso DF, Skilton G, Farias EF, de Bal Kier Joffe E, Gomez DE: Antimetastatic effect of desmopressin in a mouse mammary tumor model. Breast Cancer Res Treat 57: 271-275, 1999
39. Soule HD, Maloney TM, Wolman SR, Peterson WD, Jr., Brenz R, McGrath CM, Russo J, Pauley RJ, Jones RF, Brooks SC: Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 50: 6075-6086, 1990
40. Khanuja PS, Lehr JE, Soule HD, Gehani SK, Noto AC, Choudhury S, Chen R, Pienta KJ: Nuclear matrix proteins in normal and breast cancer cells. Cancer Res 53: 3394-3398, 1993
41. Mackinnon AC, Tufail-Hanif U, Lucas CD, Jodrell D, Haslett C, Sethi T: Expression of V(1A) and GRP receptors leads to cellular transformation and increased sensitivity to substance-P analogue-induced growth inhibition. Br J Cancer 92: 522-531, 2005
42. Zhao JJ, Gjoerup OV, Subramanian RR, Cheng Y, Chen W, Roberts TM, Hahn WC: Human mammary epithelial cell transformation through the activation of phosphatidylinositol 3-kinase. Cancer Cell 3: 483-495, 2003
43. Nicolas P, Camier M, Lauber M, Masse MJ, Mohring J, Cohen P: Immunological identification of high molecular weight forms common to bovine neurophysin and vasopressin. Proc Natl Acad Sci USA 77: 2587-2591, 1980
44. Moore GJ, Rosenior JC: Characterization of the "giant precursors" (70-80 K) of vasopressin and oxytocin in the rat hypothalamus. Prog Brain Res 60: 253-256, 1983
45. Rosenior JC, North WG, Moore GJ: Biosynthesis of oxytocin and oxytocin-neurophysin in homozygous Brattleboro rats. Ann N Y Acad Sci 394: 183-187, 1982
46. Camier M, Lauber M, Mohring J, Cohen P: Evidence for higher molecular weight immunoreactive forms of vasopressin in the mouse hypothalamus. Relationships with putative proneurophysins. FEBS Lett 108: 369-373, 1979
47. Lauber M, Camier M, Cohen P: Immunological and biochemical characterization of distinct high molecular weight forms of neurophysin and somatostatin in mouse hypothalamus extracts. FEBS Lett 97: 343-347, 1979
48. Verbalis JG, Robinson AG: Characterization of neurophysin-vasopressin prohormones in human posterior pituitary tissue. J Clin Endocrinol Metab 57: 115-123, 1983
49. Friberg MA, Spiess M, Rutishauser J: Degradation of wild-type vasopressin precursor and pathogenic mutants by the proteasome. J Biol Chem 279: 19441-19447, 2004
50. Starzec AB, Spanakis E, Nehme A, Salle V, Veber N, Mainguene C, Planchon P, Valette A, Prevost G, Israel L: Proliferative responses of epithelial cells to 8-bromo-cyclic AMP and to a Phorbol ester change during breast pathogenesis. J. Cell Physiol 161: 31-38, 1994
51. Song Z, Sidorowicz HE, Sladek CD: cAMP stimulation of vasopressin and oxytocin release and regulation of vasopressin mRNA stability: role of auto-facilitation. J Neuroendocrinol 13: 158-165, 2001
52. Erkut ZA, Gabreels BA, Eikelenboom J, van Leeuwen FW, Swaab DF: Glucocorticoid treatment is associated with decreased expression of processed AVP but not of proAVP, neurophysin or oxytocin in the human hypothalamus: are PC1 and PC2 involved? Neuroendocrinol Lett 23: 33-44, 2002
53. Cwikel BJ, Habener JF: Provasopressin-neurophysin II processing is cell-specific in heterologous cell lines expressing a metallothionein- vasopressin fusion gene. J Biol Chem 262: 14235-14240, 1987
54. Andersen MK, Sorensen JB: Development of syndrome of inappropriate secretion of antidiuretic hormone during progression of metastatic breast cancer. Acta Oncol 36: 535-537, 1997
55. Howard AC, Laing RW, Hussain FN: Breast carcinoma presenting with inappropriate ADH secretion. Eur J Cancer 29A: 2339, 1993
56. Gupta A, Sasarula S, Rao PV: The syndrome of inappropriate secretion of antidiuretic hormone in a case of carcinoma of the breast. J Assoc Physicians India 34: 441-442, 1986
57. Du J, Keegan BP, North WG: Key peptide processing enzymes are expressed by breast cancer cells. Cancer Lett 165: 211-218, 2001
58. Seufferlein T, Rozengurt E: Galanin, neurotensin, and phorbol esters rapidly stimulate activation of mitogen-activated protein kinase in small cell lung cancer cells. Cancer Res 56: 5758-5764, 1996
59. Chiu T, Wu SS, Santiskulvong C, Tangkijvanich P, Yee HF Jr., Rozengurt E Vasopressin-mediated mitogenic signaling in intestinal epithelial cells. Am J Physiol Cell Physiol 282: C434-450, 2002
60. Thibonnier M, Conarty DM, Plesnicher CL: Mediators of the mitogenic action of human V(1) vascular vasopressin receptors. Am J Physiol Heart Circ Physiol 279: H2529-2539, 2000
61. Gilad L, Bresler T, Gnainsky J, Smirnoff P, Schwartz B: Regulation of vitamin D receptor expression via estrogen-induced activation of the ERK 1/2 signaling pathway in colon and breast cancer cells. J Endocrinol 185: 577, 2005
62. Lu Y, Zi X, Zhao Y, Pollak M: Overexpression of ErbB2 receptor inhibits IGF-I-induced Shc-MAPK signaling pathway in breast cancer cells. Biochem Biophys Res Commun 313: 709-715, 2004
63. Zivadinovic D, Watson C: Membrane estrogen receptor-alpha levels predict estrogen-induced ERK1/2 activation in MCF-7 cells. Breast Cancer Res 7: R130-R144, 2005
64. Folny V, Raufaste D, Lukovic L, Pouzet B, Rochard P, Pascal M, Serradeil-Le Gal C: Pancreatic vasopressin V1b receptors: characterization in In-R1-G9 cells and localization in human pancreas. Am J Physiol Endocrinol Metab 285: E566-576, 2003
65. Bunn PA, Jr., Dienhart DG, Chan D, Tagawa M, Jewett P: Effects of neuropeptides on human lung and breast cancer cells. J Natl Cancer Inst Monogr : 145-151, 1992